339306-30-8
339306-30-8
Chemical Structure
Lorvotuzumab
Synonym(s): Anti-NCAM1/ CD56 Reference Antibody (lorvotuzumab)
- CAS No.: 339306-30-8
- Formula:N/A
- Molecular Weight:(146.44 kDa)
IUPAC Name: oxepan-2-one-4,4,5,5,6,6-d6
SMILES: [Lorvotuzumab]
Biological Activity: Lorvotuzumab (Anti-NCAM1/CD56 Reference Antibody (lorvotuzumab)) is a humanized monoclonal antibody that binds CD56 (NCAM1). Lorvotuzumab can be used to synthesize an ADC compound, Lorvotuzumab mertansine[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Lorvotuzumab | 99.77% | Lorvotuzumab (Anti-NCAM1/CD56 Reference Antibody (lorvotuzumab)) is a humanized monoclonal antibody that binds CD56 (NCAM1). Lorvotuzumab can be used to synthesize an ADC compound, Lorvotuzumab mertansine. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. James I Geller, et al. ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma-A Children's Oncology Group study. Cancer. 2020 Dec 15;126(24):5303-5310. [Content Brief]
Keywords
